Malaria remains a major global public health concern, particularly in low- and middle-income countries, where it continues to cause substantial morbidity and mortality. Central to malaria control and elimination efforts is the sustained effectiveness of antimalarial drugs. However, the emergence and spread of antimalarial drug resistance, especially in Plasmodium falciparum, pose a serious threat to success made in disease control. This narrative review synthesizes existing evidence on the historical evolution of antimalarial drugs, the molecular mechanisms underlying resistance, emerging resistance challenges, and future directions for resistance containment. The review traces the development of antimalarial therapeutics from early quinoline compounds to modern artemisinin-based combination therapies (ACTs), and highlights how drug pressure has driven the selection of resistant parasite strains. Particular emphasis focused on well-characterized molecular resistance markers, which include Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, and the kelch13 gene. The mechanisms through which these genetic alterations reduce susceptibility to antimalarial drugs are discussed in detail. In addition, the review examines current strategies and proposes future approaches to mitigate the spread of resistance, including strengthened molecular surveillance, optimized drug use, integrated vector control, and investment in novel therapeutic development. Overall, this synthesis underscores the urgent need for a coordinated global efforts to monitor, understand, and counteract antimalarial drug resistance.
Patrick et al. (Fri,) studied this question.